Corebridge Financial Inc. Invests $89,000 in Inhibrx, Inc. (NASDAQ:INBX)

Corebridge Financial Inc. purchased a new position in Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,765 shares of the company’s stock, valued at approximately $89,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. purchased a new position in Inhibrx in the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. purchased a new position in Inhibrx during the 4th quarter worth $47,000. New York State Common Retirement Fund acquired a new stake in Inhibrx in the fourth quarter valued at about $53,000. Exchange Traded Concepts LLC acquired a new stake in shares of Inhibrx in the 4th quarter valued at approximately $148,000. Finally, Rhumbline Advisers purchased a new stake in shares of Inhibrx during the 4th quarter worth $228,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Trading Down 0.8 %

Shares of NASDAQ:INBX opened at $11.79 on Wednesday. Inhibrx, Inc. has a one year low of $10.80 and a one year high of $34.90. The business’s fifty day moving average price is $13.20 and its two-hundred day moving average price is $14.26.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million during the quarter. As a group, sell-side analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.